Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 3,845Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 1Farxiga/Forxiga

02 8Farxiga/Forxiga

03 7Forxiga

04 2Qtern

PharmaCompass

01

Brand Name : Farxiga/Forxiga

Dapagliflozin

arrow
Antibody Engineering
Not Confirmed

Brand Name : Farxiga/Forxiga

arrow
Antibody Engineering
Not Confirmed

Dapagliflozin

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 1,959

2019 Revenue in Millions : 1,543

Growth (%) : 27

blank

02

Brand Name : Farxiga/Forxiga

Dapagliflozin

arrow
Antibody Engineering
Not Confirmed

Brand Name : Farxiga/Forxiga

arrow
Antibody Engineering
Not Confirmed

Dapagliflozin

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 3,000

2020 Revenue in Millions : 1,959

Growth (%) : 53

blank

03

Brand Name : Forxiga

Dapagliflozin

arrow
Antibody Engineering
Not Confirmed

Brand Name : Forxiga

arrow
Antibody Engineering
Not Confirmed

Dapagliflozin

Main Therapeutic Indication : Diabetes

Currency : USD

2020 Revenue in Millions : 198

2019 Revenue in Millions : 163

Growth (%) : 22

blank

04

Brand Name : Forxiga

Dapagliflozin

arrow
Antibody Engineering
Not Confirmed

Brand Name : Forxiga

arrow
Antibody Engineering
Not Confirmed

Dapagliflozin

Main Therapeutic Indication : Diabetes

Currency : USD

2021 Revenue in Millions : 274

2020 Revenue in Millions : 190

Growth (%) : 55

blank

05

Brand Name : Forxiga

Dapagliflozin

arrow
Antibody Engineering
Not Confirmed

Brand Name : Forxiga

arrow
Antibody Engineering
Not Confirmed

Dapagliflozin

Main Therapeutic Indication : Diabetes

Currency : USD

2022 Revenue in Millions : 400

2021 Revenue in Millions : 274

Growth (%) : 46

blank

06

Brand Name : Farxiga/Forxiga

Dapagliflozin

arrow
Antibody Engineering
Not Confirmed

Brand Name : Farxiga/Forxiga

arrow
Antibody Engineering
Not Confirmed

Dapagliflozin

Main Therapeutic Indication : Diabetes

Currency : USD

2022 Revenue in Millions : 4,381

2021 Revenue in Millions : 3,000

Growth (%) : 46

blank

07

Brand Name : Farxiga/Forxiga

Dapagliflozin

arrow
Antibody Engineering
Not Confirmed

Brand Name : Farxiga/Forxiga

arrow
Antibody Engineering
Not Confirmed

Dapagliflozin

Main Therapeutic Indication : Diabetes

Currency : USD

2023 Revenue in Millions : 5,963

2022 Revenue in Millions : 4,381

Growth (%) : 36

blank

08

Brand Name : Forxiga

Dapagliflozin

arrow
Antibody Engineering
Not Confirmed

Brand Name : Forxiga

arrow
Antibody Engineering
Not Confirmed

Dapagliflozin

Main Therapeutic Indication : Diabetes

Currency : USD

2023 Revenue in Millions : 488

2022 Revenue in Millions : 400

Growth (%) : 39

blank

09

Brand Name : Farxiga/Forxiga

Dapagliflozin

arrow
Antibody Engineering
Not Confirmed

Brand Name : Farxiga/Forxiga

arrow
Antibody Engineering
Not Confirmed

Dapagliflozin

Main Therapeutic Indication : Diabetes

Currency : USD

2015 Revenue in Millions : 0

2014 Revenue in Millions : 492

Growth (%) : New Launch

blank

10

Brand Name : Farxiga/Forxiga

Dapagliflozin

arrow
Antibody Engineering
Not Confirmed

Brand Name : Farxiga/Forxiga

arrow
Antibody Engineering
Not Confirmed

Dapagliflozin

Main Therapeutic Indication : Diabetes

Currency : USD

2017 Revenue in Millions : 1,074

2016 Revenue in Millions : 835

Growth (%) : 29

blank